Makoto Ueno

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 1K citations · Full text

Medicine, Oncology, Pharmacology +8

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies

Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno et al. · International Journal of Cancer · 2020 · 498 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda et al. · Nature Medicine · 2020 · 366 citations

Medicine, Molecular Genetics, Oncology +17

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 334 citations

Medicine, Oncology, Chemotherapy +7

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno, Masafumi Ikeda, Chigusa Morizane et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 332 citations

Medicine, Oncology, Chemotherapy +5